The Indian pharmaceutical industry plays a significant role globally, with a 20% share in the export of generic drugs and a 60% share in the supply of low-cost vaccines. Due to affordable healthcare and drugs, India has a 36% lower per person disease burden (DALY), as per data accumulated in 1990-2016. It is the third largest pharma player in terms of Volume and 14th largest in terms of Value. In 2021-22, the Indian pharma industry had a total market size of USD 50 Bn. It creates 2.7 million jobs created directly and indirectly.
The Indian pharmaceutical industry has seen a profound transformation driven by globalization, technological progress, regulatory changes, and increased demand for healthcare products
From established giants leading the way in generics and bulk drugs to innovative startups tackling niche markets and cutting-edge therapies, the Indian pharma industry caters to a global audience. This rich ecosystem fosters healthy competition, fuels research and development, and ultimately delivers a wide array of affordable medicines to patients worldwide
Exports
• India's pharmaceutical exports in 2023-24: $27.9 billion; 9.67% increase from 2022-23
•The top 5 export markets in 2023-24: US, Uk, Netherlands, South Africa, and Brazil
The Vision 2030 for the Indian Pharmaceutical Industry sets ambitious targets that include – reaching a market size of USD 120-130 billion by 2030 and enhancing its global market share to approximately 7.0% by 2030 from the current 3.61%.
Supply chain, Mfg., Quality
Innovation & R&D
Trade, IP, Patents
Sustainability and Social Responsibility
Skilling / Training & Employment
Investors keen on exploring opportunities in the Indian Pharma Market can acquaint themselves with key policies and schemes governing the industry.
PLI Scheme for promotion of domestic manufacturing of critical KSMs /DIs / APIs in India
To promote self-reliance and reduce import dependence in critical APIs. The scheme intends to boost domestic manufacturing of identified KSMs, Drug Intermediates and APIs by attracting large investments in the sector and thereby reduce India’s import dependence in critical APIs.
Total committed investment: INR 4,138.41 Cr
Actual investment up to Sep 2022: INR 1,707.37 Cr
Impact: A total number of 249 applications were received under the scheme for the 41 products spread across four target segments. Out of 249 applications, 51 have been approved and employment generation of around 10,598 persons is expected.
PLI Scheme for Promoting Domestic Manufacturing of Medical devices
To boost domestic manufacturing and attract large investments in the Medical Devices Sector.
Total committed investment: INR 4,138 Cr
Actual investment up to Sep 2022: INR 1,707 Cr
Impact: In total 42 applications were received under the scheme, out of these 21 applications have been approved with a total committed investment of Rs. 1,058.97 crore and expected employment generation of around 6,411 persons
PLI Scheme for Pharmaceuticals
To provide financial incentives to eligible manufacturers for increasing domestic production of identified bulk drugs and APIs, thereby boosting indigenous manufacturing capabilities.
Total committed investment: INR 17,425 Cr
Actual investment up to Sep 2022: INR 15,164
Impact: In total 271 applications have been received and Fifty-five (55) applicants have been selected under the scheme including 20 MSMEs. The scheme is also expected to bring in investment of more than 17,000 crore in the pharmaceutical sector.
Scheme for Bulk Drug Parks
To provide financial assistance and infrastructure support for the development of bulk drug parks, including common facilities and utilities, to attract investments from pharmaceutical companies.
Financial outlay of: INR 3000 Cr
Impact: Strengthened domestic manufacturing of bulk drugs and APIs, reduced import dependency, creation of employment opportunities, and enhanced competitiveness of the Indian pharmaceutical industry.
Pradhan Mantri Bhartiya Janaushadhi Pariyojana
To make quality medicines, consumables, and surgical items available at affordable prices for all and ensure easy availability of the menstrual health services to all women across India.
Financial outlay of: INR 490 Cr
Impact: (2021-2022)
